Samsung Bioepis Co . , Ltd . today announced that the European Medicines Agency s ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion on Benepali ? ? a biosimilar version of Enbrel ? ( etanercept ) , previously known as SB4 ? for the treatment of rheumatoid arthritis , psoriatic arthritis , axial spondyloarthritis ( ankylosing spondylitis and non radiographic axial spondyloarthritis ) and plaque psoriasis . This marks the first time the CHMP has adopted a positive opinion on an etanercept biosimilar .
